Payment overview · 2025
General Payments
$284.83
15 reported records · 7 companies
Healthcare provider profile · identity verified
Scott Pauly, MD
Allopathic & Osteopathic Physicians|Family Medicine · HUTCHINSON, KS · NPI 1720390057
Verified facts
What the public records show
CMS Open Payments records show Scott Pauly, MD received $284.83 in general payments during 2025 across 15 reported records.
ABIOMED accounted for 27.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABIOMED | Unresolved — no canonical attribution shown | $79.45 | 27.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $79.11 | 27.8% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.74 | 18.2% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$27.08 | 9.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.39 | 6.5% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $15.31 | 5.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.75 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $284.83 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $79.11 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.59 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $27.08 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1513 | 365 |
| Levothyroxine Sodium | Levothyroxine Sodium | 773 | 181 |
| Lisinopril | Lisinopril | 753 | 189 |
| Losartan Potassium | Losartan Potassium | 583 | 151 |
| Metformin Hcl | Metformin Hcl | 575 | 143 |
| Omeprazole | Omeprazole | 553 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 526 | 125 |
| Gabapentin | Gabapentin | 495 | 108 |
| Tamsulosin Hcl | Tamsulosin Hcl | 475 | 104 |
| Pantoprazole Sodium | Pantoprazole Sodium | 430 | 99 |
| Sertraline Hcl | Sertraline Hcl | 340 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 330 | 90 |
| Potassium Chloride | Potassium Chloride | 320 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 295 | 65 |
| Furosemide | Furosemide | 293 | 67 |
| Simvastatin | Simvastatin | 268 | 74 |
| Glimepiride | Glimepiride | 265 | 74 |
| Duloxetine Hcl | Duloxetine Hcl | 256 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 236 | 59 |
| Trazodone Hcl | Trazodone Hcl | 236 | 55 |
| Eliquis | Apixaban | 234 | 23 |
| Atenolol | Atenolol | 212 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 200 | 52 |
| Finasteride | Finasteride | 189 | 46 |
| Tramadol Hcl | Tramadol Hcl | 182 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 162 | 42 |
| Allopurinol | Allopurinol | 158 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 156 | 41 |
| Donepezil Hcl | Donepezil Hcl | 154 | 32 |
| Carvedilol | Carvedilol | 131 | 31 |
| Alendronate Sodium | Alendronate Sodium | 128 | 27 |
| Bupropion Xl | Bupropion Hcl | 123 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 123 | 25 |
| Mirtazapine | Mirtazapine | 109 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 28 |
| Prednisone | Prednisone | 108 | 58 |
| Meloxicam | Meloxicam | 105 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 34 |
| Warfarin Sodium | Warfarin Sodium | 101 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 100 | 29 |
| Famotidine | Famotidine | 98 | 27 |
| Spironolactone | Spironolactone | 94 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 30 |
| Montelukast Sodium | Montelukast Sodium | 93 | 24 |
| Lovastatin | Lovastatin | 89 | 20 |
| Levetiracetam | Levetiracetam | 86 | suppressed |
| Glipizide | Glipizide | 80 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 29 |
| Amiodarone Hcl | Amiodarone Hcl | 77 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 76 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 75 | 20 |
| Topiramate | Topiramate | 75 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 16 |
| Buspirone Hcl | Buspirone Hcl | 71 | 12 |
| Ozempic | Semaglutide | 70 | 11 |
| Metformin Hcl Er | Metformin Hcl | 68 | 16 |
| Clonazepam | Clonazepam | 65 | 13 |
| Alprazolam | Alprazolam | 59 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 56 | 13 |
| Trulicity | Dulaglutide | 56 | 12 |
| Baclofen | Baclofen | 54 | suppressed |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | 16 |
| Bumetanide | Bumetanide | 51 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 15 |
| Cephalexin | Cephalexin | 47 | 36 |
| Farxiga | Dapagliflozin Propanediol | 47 | 11 |
| Rexulti | Brexpiprazole | 47 | suppressed |
| Lorazepam | Lorazepam | 44 | 17 |
| Propranolol Hcl | Propranolol Hcl | 43 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | suppressed |
| Gemfibrozil | Gemfibrozil | 41 | 11 |
| Olanzapine | Olanzapine | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 11 |
| Naproxen | Naproxen | 40 | 15 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Nystatin | Nystatin | 38 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 33 |
| Carbamazepine | Carbamazepine | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Estradiol | Estradiol | 29 | 12 |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Pentoxifylline | Pentoxifylline | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 12 |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Victoza 2-Pak | Liraglutide | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 17 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Azithromycin | Azithromycin | 16 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 14 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Klor-Con M15 | Potassium Chloride | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Indapamide | Indapamide | 12 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 12 | suppressed |
| Byetta | Exenatide | 11 | suppressed |
| Cymbalta | Duloxetine Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Enbrel Sureclick | Etanercept | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $284.83 · 15 records | ABIOMED | GEMTESA, INTELLIS ADAPTIVESTIM, Omnipod, Ozempic, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error